Fanconi renotubular syndrome 2: A Patient Guide
At a Glance
Fanconi renotubular syndrome type 2 is a rare inherited kidney disorder caused by SLC34A1 changes that make the kidneys lose phosphate. Oral phosphate and regular monitoring can improve growth and bone health while helping manage calcium and kidney risks.
Fanconi renotubular syndrome type 2 (FRTS2) is an exceptionally rare, inherited kidney disorder that affects how the body manages essential minerals. It is caused by genetic changes in the SLC34A1 gene, which provides instructions for a specialized protein in the kidney’s “recycling center,” the proximal tubule [1][2]. When this protein, known as NaPi-IIa, is not working correctly, the kidneys cannot effectively pull phosphate back into the bloodstream, leading to a persistent loss of phosphate into the urine [1][3].
This loss of phosphate triggers a complex chain reaction throughout the body. To compensate for the low phosphate, the body often overproduces the active form of Vitamin D (1,25-dihydroxyvitamin D), which in turn causes the blood and urine to become overloaded with calcium [4][5]. In infants, this can manifest as poor feeding, vomiting, and a slow rate of growth, a combination often referred to as poor weight gain (or failure to thrive) [6][4]. Over time, the lack of phosphate can lead to rickets (softened or weakened bones), while the excess calcium in the urine can cause nephrocalcinosis, where calcium deposits form within the kidney tissue [2][7].
Living with FRTS2 requires a commitment to lifelong monitoring and a specialized approach to care. Because the condition is genetic, it is a permanent part of a person’s biology [8]. However, early intervention is highly effective at managing the symptoms. By using oral phosphate supplements to replace what the kidneys are losing, doctors can often normalize calcium levels and significantly improve a child’s growth and bone health [2].
While the diagnosis may feel overwhelming, there is reason for cautious optimism. Many of the most intense symptoms seen in infancy tend to stabilize or even lessen as a child grows, though the evidence base for this ultra-rare condition is small [4]. With the support of a dedicated medical team—including specialists in kidney health and genetics—patients can navigate the uncertainties and manage their health. Your role as a patient or parent is to partner with these experts, ensuring that the body’s mineral balance remains steady and monitored as you navigate the years ahead [7][8].
In this guide
6 chapters
Understanding Fanconi Renotubular Syndrome Type 2
Learn what Fanconi renotubular syndrome type 2 means, how SLC34A1 affects phosphate, symptoms in children, inheritance, and nephrocalcinosis monitoring.
Recognizing Symptoms and Warning Signs
Learn the symptoms and emergency warning signs of Fanconi renotubular syndrome 2, including high calcium, poor growth, vomiting, thirst, and bone problems.
The Biology and Diagnosis of FRTS2
Learn how FRTS2 affects phosphate transport and how doctors evaluate it using SLC34A1 testing, blood and urine results, TmP/GFR, and kidney ultrasound findings.
Treatment and Long-Term Management
Learn how Fanconi renotubular syndrome 2 is treated with oral phosphate, lab monitoring, vitamin D precautions, and kidney ultrasound follow-up for children.
Building Your Care Team
Learn how to build a Fanconi renotubular syndrome 2 care team, choose kidney and bone specialists, organize records, and prepare an emergency care plan.
Long-Term Monitoring and Growing with FRTS2
Learn how FRTS2 monitoring supports kidney function, growth, and bone health, including lab tests, ultrasounds, medication management, and adult care planning.
Common questions in this guide
What causes Fanconi renotubular syndrome type 2?
What symptoms can FRTS2 cause in babies and children?
How is Fanconi renotubular syndrome type 2 treated?
Is FRTS2 a lifelong condition, and can symptoms improve?
What should I watch for at home with FRTS2?
What does it mean if my child has one or two SLC34A1 variants?
Get notified when new evidence is published on Fanconi renotubular syndrome 2.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review.
Walker E, Hayes W, Bockenhauer D
Best practice & research. Clinical endocrinology & metabolism 2024; (38(2)):101843 doi:10.1016/j.beem.2023.101843.
PMID: 38042745 - 2
Targeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series.
Turan I, Atar M, Eltan M, et al.
Calcified tissue international 2026; (117(1)):10 doi:10.1007/s00223-025-01462-x.
PMID: 41543768 - 3
Novel Fanconi renotubular syndromes provide insights in proximal tubule pathophysiology.
Lemaire M
American journal of physiology. Renal physiology 2021; (320(2)):F145-F160 doi:10.1152/ajprenal.00214.2020.
PMID: 33283647 - 4
Presentation and outcome in carriers of pathogenic variants in SLC34A1 and SLC34A3 encoding sodium-phosphate transporter NPT 2a and 2c.
Brunkhorst M, Brunkhorst L, Martens H, et al.
Kidney international 2025; (107(1)):116-129 doi:10.1016/j.kint.2024.08.035.
PMID: 39461557 - 5
Prenatal hyperechogenic kidneys in three cases of infantile hypercalcemia associated with SLC34A1 mutations.
Hureaux M, Molin A, Jay N, et al.
Pediatric nephrology (Berlin, Germany) 2018; (33(10)):1723-1729 doi:10.1007/s00467-018-3998-z.
PMID: 29959532 - 6
Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia.
Schlingmann KP, Ruminska J, Kaufmann M, et al.
Journal of the American Society of Nephrology : JASN 2016; (27(2)):604-14 doi:10.1681/ASN.2014101025.
PMID: 26047794 - 7
Inherited Fanconi renotubular syndromes: unveiling the intricacies of hypophosphatemic rickets/osteomalacia.
Ragate DC, Memon SS, Karlekar M, et al.
Journal of bone and mineral metabolism 2024; (42(2)):155-165 doi:10.1007/s00774-023-01490-3.
PMID: 38310177 - 8
Inherited Fanconi syndrome.
Albuquerque ALB, Dos Santos Borges R, Conegundes AF, et al.
World journal of pediatrics : WJP 2023; (19(7)):619-634 doi:10.1007/s12519-023-00685-y.
PMID: 36729281
This page is for informational purposes only and does not constitute medical advice. Your child’s nephrology and genetics team should guide phosphate treatment, monitoring, and interpretation of SLC34A1 results.